Yoichiro OGAMA, Hiroki SATO, Atsunori MIYATA, Koji KIJIMA, Yuji KUMAGAI
{"title":"白莫硫地尔(一种选择性rho相关的含螺旋状蛋白激酶2抑制剂)在健康日本志愿者中的安全性、耐受性和药代动力学:Ⅰ期随机对照试验","authors":"Yoichiro OGAMA, Hiroki SATO, Atsunori MIYATA, Koji KIJIMA, Yuji KUMAGAI","doi":"10.3999/jscpt.54.5_197","DOIUrl":null,"url":null,"abstract":"Objective: To assess the safety, tolerability, and pharmacokinetics of belumosudil, a selective Rho-associated coiled-coil-containing protein kinase 2 inhibitor, in healthy Japanese male adults, a phase Ⅰ, randomized, double-blind, placebo-controlled trial was conducted.","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial\",\"authors\":\"Yoichiro OGAMA, Hiroki SATO, Atsunori MIYATA, Koji KIJIMA, Yuji KUMAGAI\",\"doi\":\"10.3999/jscpt.54.5_197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To assess the safety, tolerability, and pharmacokinetics of belumosudil, a selective Rho-associated coiled-coil-containing protein kinase 2 inhibitor, in healthy Japanese male adults, a phase Ⅰ, randomized, double-blind, placebo-controlled trial was conducted.\",\"PeriodicalId\":14602,\"journal\":{\"name\":\"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3999/jscpt.54.5_197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3999/jscpt.54.5_197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Safety, Tolerability, and Pharmacokinetics of Belumosudil, a Selective Rho-associated Coiled-coil-containing Protein Kinase 2 Inhibitor, in Healthy Japanese Volunteers: A PhaseⅠ, Randomized, Controlled Trial
Objective: To assess the safety, tolerability, and pharmacokinetics of belumosudil, a selective Rho-associated coiled-coil-containing protein kinase 2 inhibitor, in healthy Japanese male adults, a phase Ⅰ, randomized, double-blind, placebo-controlled trial was conducted.